PBCay One’s CRISPR Therapeutics CRSP Stock Holding History

PBCay One’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-165,000	Closed	-$10.3M	–	9
2023 Q4	$10.3M	Buy	+165,000	New	+$9.12M	2.26%	8

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBCay One's CRSP Position: Q1 2024 in Review

PBCay One sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 165,000 shares — an estimated $10.3M sold.

PBCay One first reported a position in CRSP in Q4 2023 and held it in 1 quarter. The position peaked at $10.3M in Q4 2023. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

PBCay One reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
PBCay One sold 165,000 CRISPR Therapeutics shares in Q1 2024, an estimated $10.3M.
PBCay One first reported a position in CRISPR Therapeutics in Q4 2023 and held it in 1 quarter.
PBCay One's CRISPR Therapeutics position peaked at $10.3M in Q4 2023.
484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on PBCay One's 13F filing for Q1 2024, filed 30 Apr 2024.